Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för garenoxacin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

11 träffar

Bibliografisk träff 2015-10-30

Analysis of garenoxacin distribution in the mediastinum using endobronchial ultrasound-guided transbronchial needle aspiration.

Endo S, Sasaki T, Onishi K, Kazebayashi Y, Hirai N, Minami Y, Toyoshima E, Yamamoto Y, Kishino S, Ohsaki Y.

Int J Antimicrob Agents · letter · DOI 10.1016/j.ijantimicag.2015.10.001

Bibliografisk träff 2015-06-01

Pharmacokinetic study of garenoxacin in severe renal failure patients.

Yamagishi Y, Hagihara M, Hamada Y, Kimura Y, Imai H, Mikamo H.

Jpn J Antibiot · randomized controlled trial; journal article

Bibliografisk träff 2015-05-19

Comparison of garenoxacin with levofloxacin as antimicrobial prophylaxis in acute myeloid leukemia.

Uni M, Yoshimi A, Yamazaki S, Taoka K, Shinohara A, Nannya Y, Nakamura F, Kurokawa M.

Jpn J Clin Oncol · comparative study; journal article · DOI 10.1093/jjco/hyv071

Bibliografisk träff 2015-05-01

A prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India.

Hajare A, Gupta A, Patil S, Krishnaprasad K, Bhargava A.

Int J Appl Basic Med Res · research-article; journal article · DOI 10.4103/2229-516x.157151

Bibliografisk träff 2014-01-01

Garenoxacin.

Vora A.

J Assoc Physicians India · journal article

Bibliografisk träff 2011-11-15

In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.

Fukuda Y, Takahata M, Sugiura Y, Shinmura Y, Nomura N.

Int J Antimicrob Agents · comparative study; journal article · DOI 10.1016/j.ijantimicag.2011.09.021

Bibliografisk träff 2011-07-28

Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.

Tanigawara Y, Nozawa K, Tsuda H.

Eur J Clin Pharmacol · clinical trial, phase iii; clinical trial, phase ii; research-article; validation study; clinical trial, phase i; journal article · DOI 10.1007/s00228-011-1095-3

Bibliografisk träff 2011-07-08

Anti-inflammatory effects of garenoxacin on IL-8 production and ERK1/2 activation induced by lipopolysaccharides in A549 and THP-1 cells.

Hara S, Ishimatsu Y, Mukae H, Sakamoto N, Kakugawa T, Fujita H, Hara A, Kohno S.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2011.06.046

Bibliografisk träff 2002-01-01

Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756).

Hayashi K, Takahata M, Kawamura Y, Todo Y.

Arzneimittelforschung · journal article · DOI 10.1055/s-0031-1299988

Bibliografisk träff 2001-12-01

T-3811. Toyama/Bristol-Myers Squibb.

Frechette R.

Curr Opin Investig Drugs · review; journal article

Bibliografisk träff 2001-11-01

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods.

Deshpande L, Biedenbach DJ, Jones RN.

Int J Antimicrob Agents · journal article · DOI 10.1016/s0924-8579(01)00438-1